{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T04:32:13Z","timestamp":1793939533781,"version":"4.8.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007316","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA023074"],"award-info":[{"award-number":["P30 CA023074"]}],"id":[{"id":"10.13039\/100007316","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.bbmt.2018.08.028","type":"journal-article","created":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T00:24:04Z","timestamp":1536193444000},"page":"94-99","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":174,"title":["Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic Transplantation"],"prefix":"10.1016","volume":"25","author":[{"given":"Awais","family":"Ijaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4062-6895","authenticated-orcid":false,"given":"Ali Younas","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1571-5378","authenticated-orcid":false,"given":"Saad Ullah","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warda","family":"Faridi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Asad","family":"Fraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Usman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Junaid","family":"Tariq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seren","family":"Durer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ceren","family":"Durer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atlantis","family":"Russ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia Nunes Cavalcante","family":"Parr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeeshan","family":"Baig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FNU","family":"Sagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeeshan","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"McBride","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6914-7439","authenticated-orcid":false,"given":"Faiz","family":"Anwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2018.08.028_bib0001","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1182\/blood-2008-07-168468","article-title":"CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation","volume":"113","author":"Bashey","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.08.028_bib0002","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1056\/NEJMoa1601202","article-title":"Ipilimumab for patients with relapse after allogeneic transplantation","volume":"375","author":"Davids","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2018.08.028_bib0003","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1586\/ehm.10.32","article-title":"Relapse after allogeneic stem cell transplantation","volume":"3","author":"Barrett","year":"2010","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.bbmt.2018.08.028_bib0004","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11899-017-0362-5","article-title":"Immune checkpoint blockade and hematopoietic stem cell transplant","volume":"12","author":"Merryman","year":"2017","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.bbmt.2018.08.028_bib0005","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1182\/blood-2016-09-738385","article-title":"Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed\/refractory lymphoma","volume":"129","author":"Merryman","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.08.028_bib0006","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2018-02-811174","article-title":"Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil","volume":"132","author":"Herbaux","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.08.028_bib0007","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1182\/blood-2017-01-761346","article-title":"PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD","volume":"130","author":"Haverkos","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.08.028_bib0008","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1182\/blood-2016-11-749556","article-title":"Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma","volume":"129","author":"Herbaux","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.08.028_bib0009","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1158\/1078-0432.CCR-17-2777","article-title":"Ipilimumab plus lenalidomide after allogeneic and autologous stem cell transplantation for patients with lymphoid malignancies","volume":"24","author":"Khouri","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2018.08.028_bib0010","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1093\/annonc\/mdx341","article-title":"Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience","volume":"28","author":"Bek\u00f6z","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2018.08.028_bib0011","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1634\/theoncologist.2017-0004","article-title":"FDA approval summary: nivolumab for the treatment of relapsed or progressive classical Hodgkin lymphoma","volume":"22","author":"Kasamon","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.bbmt.2018.08.028_bib0012","doi-asserted-by":"crossref","first-page":"4571","DOI":"10.1182\/blood.V128.22.4571.4571","article-title":"Checkpoint inhibitor therapy and graft versus host disease in allogeneic bone marrow transplant recipients of haploidentical and matched products with post-transplant cyclophosphamide","volume":"128","author":"Schoch","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.bbmt.2018.08.028_bib0013","first-page":"275","article-title":"Optimizing checkpoint blockade as a treatment for relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation","volume":"130","author":"Davids","year":"2017","journal-title":"Blood."},{"key":"10.1016\/j.bbmt.2018.08.028_bib0014","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1182\/blood.V128.22.3502.3502","article-title":"Outcomes of allogeneic hematopoietic stem cell transplantation (HSCT) after treatment with nivolumab for relapsed\/refractory Hodgkin lymphoma","volume":"128","author":"Armand","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.08.028_bib0015","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/bmt.2015.346","article-title":"Major clinical response to nivolumab in relapsed\/refractory Hodgkin lymphoma after allogeneic stem cell transplantation","volume":"51","author":"Yared","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.08.028_bib0016","doi-asserted-by":"crossref","first-page":"13260","DOI":"10.18632\/oncotarget.7177","article-title":"Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplant is safe and effective","volume":"7","author":"Villasboas","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbmt.2018.08.028_bib0017","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/bmt.2016.111","article-title":"Fatal GvHD induced by PD-1 inhibitor pembrolizumab in a patient with Hodgkin's lymphoma","volume":"51","author":"Singh","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.08.028_bib0018","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s12185-017-2181-9","article-title":"Successful treatment with low-dose nivolumab in refractory Hodgkin lymphoma after allogeneic stem cell transplantation","volume":"106","author":"Onizuka","year":"2017","journal-title":"Int J Hematol"},{"key":"10.1016\/j.bbmt.2018.08.028_bib0019","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","article-title":"PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing I-asparaginase","volume":"129","author":"Kwong","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.08.028_bib0020","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40425-017-0211-z","article-title":"PD-1 blockade induces remissions in relapsed classical Hodgkin lymphoma following allogeneic hematopoietic stem cell transplantation","volume":"5","author":"Godfrey","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.bbmt.2018.08.028_bib0021","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1007\/s00277-016-2764-1","article-title":"Pembrolizumab for relapsed anaplastic large cell lymphoma after allogeneic haematopoietic stem cell transplantation: efficacy and safety","volume":"95","author":"Chan","year":"2016","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bbmt.2018.08.028_bib0022","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/bmt.2017.107","article-title":"MRD response in a refractory paediatric T-ALL patient through anti-programmed cell death 1 (PD-1) Ab treatment associated with induction of fatal GvHD","volume":"52","author":"Boekstegers","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.08.028_bib0023","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26257","article-title":"Tolerance and effectiveness of nivolumab after pediatric T\u2010cell replete, haploidentical, bone marrow transplantation: a case report","volume":"64","author":"Shad","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bbmt.2018.08.028_bib0024","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/bmt.2015.266","article-title":"Nivolumab in a patient with refractory Hodgkin's lymphoma after allogeneic stem cell transplantation","volume":"51","author":"Angenendt","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.08.028_bib0025","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/bmt.2016.274","article-title":"PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation","volume":"52","author":"Albring","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.08.028_bib0026","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/bmt.2017.44","article-title":"Nivolumab before and after allogeneic hematopoietic cell transplantation","volume":"52","author":"Covut","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.08.028_bib0027","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1038\/bmt.2017.69","article-title":"Nivolumab salvage therapy before or after allogeneic stem cell transplantation in Hodgkin lymphoma","volume":"52","author":"El Cheikh","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.08.028_bib0028","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1182\/blood-2008-07-163212","article-title":"The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation","volume":"113","author":"Ringd\u00e9n","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.08.028_bib0029","unstructured":"Center for International Blood and Marrow Transplant Research (CIBMTR). Progress report January\u2010December 2008. Available at:https:\/\/www.cibmtr.org\/About\/AdminReports\/Documents\/2008_CIBMTR_Annual_R.pdf. Accessed April 14, 2018."},{"key":"10.1016\/j.bbmt.2018.08.028_bib0030","unstructured":"DSouza A, Fretham C. Current uses and outcomes of hematopoietic cell transplantation (HCT): CIBMTR Summary Slides, 2017. Available at: http:\/\/www.cibmtr.org. Accessed April 18, 2018."},{"key":"10.1016\/j.bbmt.2018.08.028_bib0031","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1182\/blood-2013-05-500801","article-title":"Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality","volume":"122","author":"Saha","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.08.028_bib0032","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.4049\/jimmunol.171.3.1272","article-title":"Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism","volume":"171","author":"Blazar","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.bbmt.2018.08.028_bib0033","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.bbmt.2010.08.005","article-title":"CTLA-4 blockade following relapse of malignancy after allogeneic stem cell transplantation is associated with T cell activation but not with increased levels of T regulatory cells","volume":"17","author":"Zhou","year":"2011","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879118305305?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879118305305?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:04:28Z","timestamp":1761059068000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879118305305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S1083879118305305"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2018.08.028","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic Transplantation","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2018.08.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}